95 related articles for article (PubMed ID: 9324294)
1. In vitro effects of IL-12 and IL-2 on NK cells, cytokine release and clonogenic activity in myelodysplastic syndromes (MDS).
Sarina B; Cortelezzi A; Cattaneo C; Pomati M; Silvestris I; Di Stefano M; Lambertenghi-Deliliers D; Hu C; Monza M; Maiolo AT
Leukemia; 1997 Oct; 11(10):1726-31. PubMed ID: 9324294
[TBL] [Abstract][Full Text] [Related]
2. In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients.
Cortelezzi A; Sarina B; Cattaneo C; Pomati M; Silvestris I; Soligo D; Calori R; Di Stefano M; Hu C; Monza M; Radelli L; Maiolo AT
Leukemia; 1996 Jul; 10(7):1181-9. PubMed ID: 8684000
[TBL] [Abstract][Full Text] [Related]
3. Effects of interleukin-12 on natural killer cell cytotoxicity and the production of interferon-gamma and tumour necrosis factor-alpha in patients with myelodysplastic syndromes.
Ogata K; Tamura H; Yokose N; An E; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Clark SC; Nomura T
Br J Haematol; 1995 May; 90(1):15-21. PubMed ID: 7786778
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells.
Kedar E; Rezai AR; Giorgi JV; Gale RP; Champlin RE; Mitsuyasu RT; Fahey JL
Nat Immun Cell Growth Regul; 1988; 7(1):13-30. PubMed ID: 2896298
[TBL] [Abstract][Full Text] [Related]
5. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12.
Wong EK; Eaves C; Klingemann HG
Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997
[TBL] [Abstract][Full Text] [Related]
6. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
7. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18.
Lauwerys BR; Renauld JC; Houssiau FA
Cytokine; 1999 Nov; 11(11):822-30. PubMed ID: 10547269
[TBL] [Abstract][Full Text] [Related]
8. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production.
Klingemann HG; Neerunjun J; Schwulera U; Ziltener HJ
Leukemia; 1993 Sep; 7(9):1389-93. PubMed ID: 8371589
[TBL] [Abstract][Full Text] [Related]
9. Effects of interleukin 2 on myelodysplastic syndromes.
Ogata K; Yokose N; Ito T; An E; Dan K; Nomura T
Leuk Res; 1993 Feb; 17(2):137-42. PubMed ID: 8429690
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endothelium.
Salvo G; Samoggia P; Masciulli R; Boccoli G; Allavena P; Mariani G; Bullo A; Montesoro E; Bulgarini D; Carlini P
Eur J Cancer; 1992; 28A(4-5):818-25. PubMed ID: 1524901
[TBL] [Abstract][Full Text] [Related]
11. Generation of mouse natural killer (NK) cell activity: effect of interleukin-2 (IL-2) and interferon (IFN) on the in vivo development of natural killer cells from bone marrow (BM) progenitor cells.
Riccardi C; Giampietri A; Migliorati G; Cannarile L; D'Adamio L; Herberman RB
Int J Cancer; 1986 Oct; 38(4):553-62. PubMed ID: 2944847
[TBL] [Abstract][Full Text] [Related]
12. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
Klingemann HG; Deal H; Reid D; Eaves CJ
Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro: synergism between interleukin (IL)-12 and IL-15 or IL-12 and IL-2.
Seidel MG; Freissmuth M; Pehamberger H; Micksche M
Naunyn Schmiedebergs Arch Pharmacol; 1998 Sep; 358(3):382-9. PubMed ID: 9774227
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-17 enhances the production of interferon-γ and tumour necrosis factor-α by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes.
Zhang Z; Li X; Guo J; Xu F; He Q; Zhao Y; Yang Y; Gu S; Zhang Y; Wu L; Chang C
Eur J Haematol; 2013 May; 90(5):375-84. PubMed ID: 23331180
[TBL] [Abstract][Full Text] [Related]
15. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
[TBL] [Abstract][Full Text] [Related]
16. Impact of Bone Marrow Natural Killer Cells (NK); Soluble TNF-α and IL-32 Levels in Myelodysplastic Syndrome Patients.
Aref S; Khaled N; Al Gilany AH; Ayed M; Abouzeid T; Attia D
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2949-2953. PubMed ID: 33112553
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome.
Flores-Figueroa E; Gutiérrez-Espíndola G; Montesinos JJ; Arana-Trejo RM; Mayani H
Leuk Res; 2002 Jul; 26(7):677-86. PubMed ID: 12008086
[TBL] [Abstract][Full Text] [Related]
18. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15.
Dunne J; Lynch S; O'Farrelly C; Todryk S; Hegarty JE; Feighery C; Doherty DG
J Immunol; 2001 Sep; 167(6):3129-38. PubMed ID: 11544298
[TBL] [Abstract][Full Text] [Related]
19. Natural killer (NK) cell generation in bone marrow cultures: role of IL-1 alpha.
Ayroldi E; Cannarile L; Riccardi C
Immunopharmacol Immunotoxicol; 1991; 13(4):589-606. PubMed ID: 1774437
[TBL] [Abstract][Full Text] [Related]
20. Effect of interleukin-12 on antitumor activity of human umbilical cord blood and bone marrow cytotoxic cells.
Condiotti R; Nagler A
Exp Hematol; 1998 Jul; 26(7):571-9. PubMed ID: 9657131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
